Merck's tulisokibart showed mid-stage success in hidradenitis suppurativa, with 72% high-dose patients seeing 50%+ abscess ...
NCI director Ned Sharpless as MD and Andrew Witty as chairman, while raising a $100M second opportunities fund.
ARCH and Population Health launch Somnivera with a $10.5M-upfront deal for an ex-China sleep drug from Jiangsu Nhwa.
Beam Therapeutics sued YolTech's Yuxuan Wu & Zi Jun Wang and Serapha Bio for allegedly stealing trade secrets related to ...
Former House majority leader Eric Cantor has been chosen as PhRMA’s next CEO, according to two sources familiar ...
Zealand and Roche's petrelintide peaks at 10.7% weight loss at its middle dose in Ph2, trailing Lilly's eloralintide at 20.1% ...
UniQure's shares were rocked Tuesday morning after the company revealed its experimental Huntington’s disease gene therapy ...
Breye Therapeutics raised €67.5M Series A; Aptadir raised €40M seed; Ascletis' ASC50 shows psoriasis results; Invivyd touts ...
Bio raises $48M Series A led by UPMC Enterprises & Ziff Capital to target Th17 cells via CD161+ antibody & CAD mRNA platforms ...
Fresenius Kabi will sell biosimilars for Humira, Stelara & Actemra directly to employers via Eversana's Waltz Health, with ...
Oura delays IPO citing market uncertainty despite $1.2B revenue and strong demand. Anthropic, OpenAI, Holtec, and Bamboo ...
The cash should give the Stockholm-based biotech a runway “well into 2029,” CEO Patrik Strömberg told Endpoints News in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results